ST2 and IL-33 in pregnancy and pre-eclampsia

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Granne, Ingrid ^a   Southcombe, Jennifer H ^a   Snider, James V ^b   Tannetta, Dionne S ^a   Child, Tim ^a   Redman, Christopher W G ^a   Sargent, Ian L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Critical Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 7; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 33; PROTEIN ST2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; ARTICLE; CHORION VILLUS; CLINICAL ARTICLE; CONTROLLED STUDY; EXPERIMENTAL MODEL; EXPLANT; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN TISSUE; HYPOXEMIA; PLACENTA; PLACENTA PERFUSION; PREECLAMPSIA; PREGNANCY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; REPERFUSION INJURY; SECOND TRIMESTER PREGNANCY; SYMPTOM; SYNCYTIOTROPHOBLAST; THIRD TRIMESTER PREGNANCY; BLOOD; CHEMISTRY; GENE EXPRESSION REGULATION; METABOLISM; SECRETION; SOLUBILITY;

ADULT; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKINS; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; RECEPTORS, CELL SURFACE; SOLUBILITY;

EID: 80052858602     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024463     Document Type: Article

References (44)

1. Redman CW, Sargent IL, (2005) Latest advances in understanding preeclampsia. Science 308: 1592-1594.
2. Borzychowski AM, Sargent IL, Redman CWG, (2006) Inflammation and pre-eclampsia. Seminars in fetal & neonatal medicine 11: 309-316.
3. Kakkar R, Lee RT, (2008) The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7: 827-840.
4. Xu D, Chan WL, Leung BP, Huang Fp, Wheeler R, et al. (1998) Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 187: 787.
5. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G, (2007) Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 179: 2051-2054.
6. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, et al. (2008) IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 20: 1019-1030.
7. Mildner M, Storka A, Lichtenauer M, Mlitz V, Ghannadan M, et al. (2010) Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc Res 87: 769-777.
8. Bartunek J, Delrue L, Van Durme F, Muller O, Casselman F, et al. (2008) Nonmyocardial Production of ST2 Protein in Human Hypertrophy and Failure Is Related to Diastolic Load. Journal of the American College of Cardiology 52: 2166-2174.
9. Lecart S, Lecointe N, Subramaniam A, Alkan S, Ni D, et al. (2002) Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface. Eur J Immunol 32: 2979-2987.
10. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, et al. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490.
11. Moussion C, Ortega N, Girard JP, (2008) The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One 3: e3331.
12. Pastorelli L, Garg RR, Hoang SB, Spina L, Mattioli B, et al. (2010) Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A 107: 8017-8022.
13. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM, (2009) Interleukin-33- cytokine of dual function or novel alarmin? Trends Immunol 30: 227-233.
14. Cayrol C, Girard JP, (2009) The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A 106: 9021-9026.
15. Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, et al. (2009) Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31: 84-98.
16. Beltran CJ, Nunez LE, Diaz-Jimenez D, Farfan N, Candia E, et al. (2009) Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis.
17. Brunner M, Krenn C, Roth G, Moser B, Dworschak M, et al. (2004) Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 30: 1468-1473.
18. Liew FY, Pitman NI, McInnes IB, (2010) Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol.
19. Pushparaj PN, Tay HK, H'Ng S C, Pitman N, Xu D, et al. (2009) The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci U S A 106: 9773-9778.
20. Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S-i, (2001) Identification of Human ST2 Protein in the Sera of Patients with Autoimmune Diseases. Biochemical and Biophysical Research Communications 284: 1104-1108.
21. Oshikawa K, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, et al. (2001) Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 164: 277-281.
22. Socrates T, deFilippi C, Reichlin T, Twerenbold R, Breidhardt T, et al. (2010) Interleukin family member ST2 and mortality in acute dyspnoea. J Intern Med 268: 493-500.
23. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, et al. (2003) Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107: 721-726.
24. Alves-Filho JC, Sonego F, Souto FO, Freitas A, Verri WA, et al. (2010) Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med 16: 708-712.
25. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, et al. (2004) Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109: 2186-2190.
26. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, et al. (2009) Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2: 684-691.
27. Hung TH, Skepper JN, Burton GJ, (2001) In vitro ischemia-reperfusion injury in term human placenta as a model for oxidative stress in pathological pregnancies. Am J Pathol 159: 1031-1043.
28. Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH, (2010) Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks. Ultrasound Obstet Gynecol 35: 662-670.
29. Southcombe J, Tannetta D, Redman C, Sargent I, (2011) The immunomodulatory role of syncytiotrophoblast microvesicles. PLoS One 6: e20245.
30. Hung TH, Chen SF, Liou JD, Hsu JJ, Li MJ, et al. (2008) Bax, Bak and mitochondrial oxidants are involved in hypoxia-reoxygenation-induced apoptosis in human placenta. Placenta 29: 565-583.
31. Kumar S, Tzimas MN, Griswold DE, Young PR, (1997) Expression of ST2, an Interleukin-1 Receptor Homologue, Is Induced by Proinflammatory Stimuli. Biochemical and Biophysical Research Communications 235: 474-478.
32. Melchiorre K, Sutherland GR, Baltabaeva A, Liberati M, Thilaganathan B, (2011) Maternal cardiac dysfunction and remodeling in women with preeclampsia at term. Hypertension 57: 85-93.
33. Aoki S, Hayakawa M, Ozaki H, Takezako N, Obata H, et al. (2010) ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells. Mol Cell Biochem 335: 75-81.
34. Houghton-Trivino N, Salgado DM, Rodriguez JA, Bosch I, Castellanos JE, (2010) Levels of soluble ST2 in serum associated with severity of dengue due to tumour necrosis factor alpha stimulation. J Gen Virol 91: 697-706.
35. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, et al. (1989) Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 161: 1200-1204.
36. Yagami A, Orihara K, Morita H, Futamura K, Hashimoto N, et al. (2010) IL-33 mediates inflammatory responses in human lung tissue cells. J Immunol 185: 5743-5750.
37. Borzychowski AM, Croy BA, Chan WL, Redman CW, Sargent IL, (2005) Changes in systemic type 1 and type 2 immunity in normal pregnancy and pre-eclampsia may be mediated by natural killer cells. Eur J Immunol 35: 3054-3063.
38. Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, et al. (2010) IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A 107: 18581-18586.
39. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, et al. (2007) IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A 104: 282-287.
40. Ali S, Mohs A, Thomas M, Klare J, Ross R, et al. (2011) The Dual Function Cytokine IL-33 Interacts with the Transcription Factor NF-{kappa}B To Dampen NF-{kappa}B-Stimulated Gene Transcription. J Immunol.
41. Young BC, Levine RJ, Karumanchi SA, (2010) Pathogenesis of preeclampsia. Annu Rev Pathol 5: 173-192.
42. Angelo LS, Kurzrock R, (2007) Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 13: 2825-2830.
43. Yano K, Liaw PC, Mullington JM, Shih SC, Okada H, et al. (2006) Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med 203: 1447-1458.
44. Foidart JM, Schaaps JP, Chantraine F, Munaut C, Lorquet S, (2009) Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia-a step forward but not the definitive answer. J Reprod Immunol 82: 106-111.